Baseline plasma levels of interleukin-8 in stage IV non-small-cell lung cancer patients: Relationship with nutritional status and prognosis

Nutrition and Cancer

Volumn 64, Issue 1, 2012, Pages 41-47

  Gioulbasanis, Ioannis ^a,b   Patrikidou, Anna ^a   Kitikidou, Kyriaki ^c   Papadimitriou, Konstantinos ^a   Vlachostergios, Panagiotis J ^a   Tsatsanis, Christos ^d   Margioris, Andrew N ^d   Papandreou, Christos N ^a   Mavroudis, Dimitris ^b   Georgoulias, Vassilis ^b  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^d UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 8;

AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; METASTASIS; NUTRITIONAL STATUS; OVERALL SURVIVAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; TUMOR GROWTH;

AGED; CACHEXIA; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-8; LUNG NEOPLASMS; MALE; MALNUTRITION; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUTRITION ASSESSMENT; NUTRITIONAL STATUS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84856908752     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2012.630157     Document Type: Article

References (39)

1. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy and supportive care versus supportive care alone in advanced non-small cell lung cancer. Cohrane Database Syst Rev 5, CD007309, 2010.
2. Leonard EJ and Yoshimura T. Neutrophil attractant/activation protein- 1 (NAP-1 [interleukin-8]). Am J Respir Cell Mol Biol 2, 479-486, 1990.
3. Smith DR, Polverini PJ, Kunkel SL, Orringer MB, Whyte RI,.et al. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J ExpMed 179, 1409-1415, 1994. (Pubitemid 24129558)
4. Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD,.et al. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 97, 2792-2802, 1996. (Pubitemid 26197092)
5. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA,.et al. Interleukin-8 (IL-8) as a macrophage-derived mediator of angiogenesis. Science 258, 1798-1801, 1992. (Pubitemid 23087348)
6. Strieter RM, Kunkel SL, Elner VM, Martonyi CL, Koch AE,.et al. Interleukin-8: A corneal factor that induces neovascularization. Am J Pathol 141, 1279-1284, 1992. (Pubitemid 23002612)
7. Hu DE, Hori Y, and Fan TPD: Interleukin-8 stimulates angiogenesis in rats. Inflammation 17, 135-143, 1993. (Pubitemid 23105187)
8. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, and Angeletti CA: Relation of neovascularization to metastasis of non-small-cell lung cancer. Lancet 340, 145-146, 1992.
9. Weidner N, Carroll PR, Flax J, Blumenfeld W, and Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143, 401-409, 1993. (Pubitemid 24058195)
10. Weidner N, Semple JP, Welch WR, and Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324, 1-8, 1991.
11. Zhu YM, Webster SJ, Flower D, and Woll PJ: Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br J Cancer 91, 1970-1976, 2004. (Pubitemid 40065527)
12. Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D Jr.,.et al. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 97, 1211-1216, 2003. (Pubitemid 36237306)
13. Song B, Zhang D, Wang S, Zheng H, and Wang X. Association of interleukin-8 with cachexia from patients with low-third gastric cancer. Comp Funct Genomics 212, 212345-212350, 2009.
14. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K,.et al. Impact of weight loss on circulating IL-1, IL-6, IL-8, TNF-alpha, VEGF-A, VEGF-C and midkine in gastroesophageal cancer patients. Clin Biochem 40, 1353-1360, 2007. (Pubitemid 350151421)
15. Kosacka M, Werýnska B, Golecki M, Jankowska R, and Passowicz- Muszýnska E. The incidence and pathogenesis of cancer anorexiacachexia syndrome in lung cancer. Pneumonol Alergol Pol 76, 360-365, 2008.
16. Orditura M, De Vita F, Catalano G, Infusino S, Lieto E,.et al. Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis. J Interferon Cytokine Res 22, 1129-1135, 2002. (Pubitemid 36051185)
17. Kaminska J, Kowalska M, Kotowicz B, Fuksiewicz M, Glogowski M,.et al. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF-an independent prognostic factor. Oncology 70, 115-125, 2006. (Pubitemid 43760337)
18. Boldrini L, Gisfredi S, Ursino S, Lucchi M, Mussi A,.et al. Interleukin-8 in non-small cell lung carcinoma: Relation with angiogenic pattern and p53 alterations. Lung Cancer 50, 309-317, 2005.
19. Nestĺe Nutrition Institute: MNA Mini Nutritional Assessment. Retrieved fromhttp://www.mna-elderly.com/
20. Huhmann MB and Cunningham RS: Importance of nutritional screening in treatment of cancer-related weight loss. Lancet Oncol 6, 334-343, 2005. (Pubitemid 40590271)
21. Council on Practice Quality Management Committee: Identifying patients at risk: ADA's definitions for nutrition screening and nutrition assessment. J Am Diet Assoc 94, 838-839, 1994.
22. Gioulbasanis I, Baracos VE, Giannousi Z, Xyrafas A, Martin L,.et al. Baseline nutritional evaluation in metastatic lung cancer patients: Mini Nutritional Assessment (MNA) versus weight loss history. Ann Oncol 22, 835-841, 2011.
23. Therasse P, Arbuck SG, Eisenhauer EA,Wanders J, Kaplan RS,.et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Institute 92, 205-216, 2000. (Pubitemid 30099779)
24. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE,.et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5, 649-655, 1982. (Pubitemid 13149996)
25. Berthier F, Lambert C, Genin C, and Bienvenu J. Evaluation of an automated immunoassay method for cytokine measurement using the Immulite Immunoassay system. Clin Chem Lab Med 37, 593-599, 1999. (Pubitemid 29304424)
26. Martin C. Calorie, protein, fluid, and micronutrient requirements. In: The Clinical Guide to Oncology Nutrition, McCallum P and Polisena C (eds.). Chicago: The American Dietetic Association, 2000, pp. 45-60.
27. Muscaritoli M, Bossola M, Aversa Z, Bellantone R, and Rossi Fanelli F. Prevention and treatment of cancer cachexia: New insights into and old problem. Eur J Cancer 42, 31-41, 2006. (Pubitemid 41814530)
28. Gordon J, Green S, and Goggin P. Cancer cachexia. QJM 98, 779-788, 2005. (Pubitemid 41631328)
29. Tisdale M. Mechanisms of cancer cachexia. Physiol Rev 89, 381-410, 2009.
30. Yang ZG, Blaha V, Meguid MM, Laviano A, Oler A,.et al. Interleukin- 1 alpha injection into ventromedial hypothalamic nucleus of normal rats depresses food intake and increases release of dopamine and serotonin. Pharmacol Biochem Behav 62, 61-65, 1999. (Pubitemid 29017756)
31. Ramos EJ, Suzuki S, Marks D, Inui A, Asakawa A,.et al. Cancer anorexiacachexia syndrome: Cytokines and neuropeptides. Curr Opin Nutr Metab Care 7, 427-434, 2004. (Pubitemid 40340650)
32. Illman J, Corringham R, Robinson D Jr., Davis HM, Rossi, JF,.et al. Are inflammatory cytokines the common link between cancer-associated cachexia and depression? J Support Oncol 3, 37-50, 2005. (Pubitemid 41029582)
33. Carson JA and Baltgalvis KA: Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev 38, 168-176, 2010.
34. Trikha M, Corringham R, Klein B, and Rossi JF: Targeted anti-interleukin- 6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence. Clin Cancer Res 9, 4653-4665, 2003. (Pubitemid 37323267)
35. Watchorn TM, Waddell I, and Ross JA: Proteolysis-inducing factor differentially influences transcriptional regulation in endothelial subtypes. Am J Physiol Endocrinol Metab 282, E763-E769, 2002. (Pubitemid 34654738)
36. Watchorn TM, Dowidar N, Dejong CH, Waddell ID, Garden OJ,.et al. The cachectic mediator proteolysis inducing factor activates NF-kB and STAT3 in human Kupffer cells and monocytes. Int J Oncol 27, 1105-1111, 2005.
37. WilliamsML, Torres-Duarte A, Brant LJ, Bhargava P, Marshall J,.et al. The relationship between a urinary cachectic factor and weight loss in advanced cancer patients. Cancer Invest 22, 866-870, 2004. (Pubitemid 39665351)
38. Wieland BM, Stewart GD, Skipworth RJ, Sangster K, Fearon KC,.et al. Is there a human homologue to the murine proteolysis-inducing factor? Clin Cancer Res 13, 4984-4992, 2007. (Pubitemid 47502062)
39. Werýnska B, Kosacka M, Golecki M, and Jankowska R. VEGF in the cancer anorexia-cachexia syndrome in patients with lung cancer. PneumonolAlergol Pol 74, 186-190, 2006. (Pubitemid 44504021)